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Available online 16 March 2016AbstractOsteoporosis is a metabolic bone disease characterized by decreased bone strength, leading to an increased risk of fracture. The World Health
Organization (WHO) defines osteoporosis as a bone mineral density (BMD) of 2.5 standard deviations below that of a young adults (T-score of
2.5 or lower). Severe osteoporosis is differentiated from osteoporosis by the presence of one or more fragility fractures in addition to this T-
score. However, the current WHO definition may be insufficient to reflect the diverse spectrum of osteoporosis or severe osteoporosis, which can
encompass various number and severity of prevalent fractures. To overcome these shortcomings of the WHO definition of osteoporosis, we
propose a concept of ‘advanced severe osteoporosis’, which is defined by the presence of proximal femur fragility fracture or two or more
fragility fractures in addition to BMD T-score of 2.5 or less. Based on the previous clinical trials and post-hoc analyses, we recommend
selective estrogen receptor modulators, bisphosphonates, receptor activator of nuclear factor kappa-B ligand (RANKL) monoclonal antibody,
and parathyroid hormone for the medical treatment of severe osteoporosis. In cases of advanced severe osteoporosis or osteoporosis that does not
respond to previous anti-osteoporotic treatments, we also recommend parathyroid hormone, bisphosphonates, and RANKL monoclonal anti-
body. In conclusion, we need more precise assessment of osteoporosis and further stratification of the disease by number of prevalent fractures in
addition to BMD. More aggressive managements should be provided for those with advanced severe osteoporosis.
© 2016 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Osteoporosis is a metabolic bone disease characterized by
decreased bone strength, leading to an increased risk of frac-
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).common public health problems with a progressive increase in
the elderly population. Medical-related expenses are expected
to rapidly rise around the world [1]. Osteoporosis related
fractures can cause significant morbidity and disability,
reducing the quality of life, and can even lead to death in
severe cases. If hip fracture occurs, 20e30% of patients die
within one year [2,3]. Furthermore, 40% of patients are unable
to walk independently, and 60% have difficulty with at least
one essential activity of daily living one year after hip fracture
[3].Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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previously reported that about 40% of white women and 13%
of white men in the United States have at least one fragility
fracture after 50 years of age [3]. A recent report based on the
Health Insurance Review and Assessment Service (HIRA) in
Korea documented residual lifetime probability of
osteoporosis-related fractures is 59.5% and 23.8 for Korean
women and men, respectively [4]. Asia is expected to be
seriously affected by osteoporosis-related fractures in the near
future with its rapidly aging population. It is estimated that
50% of all osteoporotic fractures will occur in Asia by 2050
[5]. Based on the Korea National Health and Nutrition Ex-
amination Survey (KNHANES), the prevalence of osteopo-
rosis in adults aged 50 years or older was 35.5% in women and
7.5% in men [6]. However, the estimated diagnosis rate of
osteoporosis is only 26.2% (women 29.9%, men 5.8%) and the
treatment rate is as low as 12.8% (women 14.4%, men 4.0%)
in Korea [6]. Despite its devastating effect on public health,
osteoporosis is still being under-diagnosed and under-treated
in modern societies.
The World Health Organization (WHO) defines osteopo-
rosis as a bone mineral density (BMD) of 2.5 standard de-
viations below that of a young adults (T-score of 2.5 or
lower) [7]. Severe osteoporosis is differentiated from osteo-
porosis by the presence of one or more fragility fractures in
addition to BMD T-score below 2.5 [7]. The presence of
fragility fractures has a clinically significant implication for
subsequent fractures. Patients with a vertebral fracture are at
about 3e5-fold higher risk for another vertebral fracture
within the following year than those without fracture [8,9].
Therefore, it is clinically more important to treat those with
prevalent fractures with medications that have clear evidence
of fracture reduction in such patients. Based on the results of
previous clinical trials, we chose four classes of pharmaco-
logical agents that have clear evidences of anti-fracture effi-
cacy in such patients and summarized the effects of those
medications (Table 1). These pharmacological agents include
selective estrogen receptor modulators (SERMs), bisphosph-
onates, receptor activator of nuclear factor kappa-B ligand
(RANKL) monoclonal antibody, and parathyroid hormone. In
this topic review, we also discuss the limitations of the current
WHO definition of severe osteoporosis and proposed a concept
of ‘advanced severe osteoporosis’ to provide a more accurate
assessment of the disease and allow more proactive
managements.
2. SERMs2.1. RaloxifeneThe Multiple Outcomes of Raloxifene (MORE) trial stud-
ied the effects of raloxifene in 7705 postmenopausal women
with osteoporosis. Raloxifene decreased the cumulative risk of
new vertebral fractures, increased BMD, and decreased
biochemical markers of bone turnover in the 36-month treat-
ment period [10]. Post hoc analyses studied the effects of
placebo, raloxifene 60 mg/day and raloxifene 120 mg/day onnew fracture risk in women with the most severe prevalent
vertebral fractures (n ¼ 614) among the MORE population.
The presence and severity of prevalent vertebral fractures were
determined from visual semiquantitative (SQ) analysis of
spinal radiographs taken at baseline. In patients with severe
baseline vertebral fractures (SQ 3), raloxifene 60 mg/day
decreased the risks of new vertebral [Relative Risk (RR) 0.74,
95% Confidence Interval (CI) 0.54e0.99; P ¼ 0.048] and
nonvertebral (clavicle, humerus, wrist, pelvis, hip, and leg)
fractures [Relative Hazard (RH) 0.53, 95% CI 0.29e0.99;
P ¼ 0.046] at 3 years [11]. The MORE study had a 12-month
blinded extension phase to further assess the cumulative ef-
fects of raloxifene on the incidence of fractures, changes in
BMD and bone turnover (n ¼ 6828). After 4 years, the cu-
mulative relative risks for new vertebral fractures were
reduced in the total study population with both raloxifene
doses (60 mg/day, 120 mg/day). For women with prevalent
vertebral fractures, the RR for new vertebral fractures was
0.66 (95% CI 0.55e0.81) with raloxifene 60 mg/day and 0.54
(95% CI 0.44e0.66) with raloxifene 120 mg/day. There was
no evidence that raloxifene treatment lowered the risk for
nonvertebral fractures in the total study population [12]. The
Continuing Outcomes Relevant to Evista (CORE) trial
assessed the effects of raloxifene on breast cancer and non-
vertebral fracture for 4 additional years beyond the 4-year
MORE osteoporosis treatment trial. Raloxifene therapy had
no effect on nonvertebral fracture risk after 8 years. However,
the risk for new nonvertebral fractures was significantly
decreased in women with prevalent vertebral fractures at the
baseline of MORE [Hazard Ratio (HR) 0.78, 95% CI
0.63e0.96] [13]. Raloxifene therapy significantly decreased
the risk of subsequent vertebral and nonvertebral fractures at 3
years in the small subgroup of women with severe vertebral
fractures at baseline. Furthermore, nonvertebral fracture risk
reduction might be maintained in some high-risk subgroups by
exploratory analyses after 8 years of raloxifene.2.2. BazedoxifeneIn a 3-year, randomized, double-blind, placebo- and active-
controlled study, healthy postmenopausal women with osteo-
porosis (n ¼ 6847, 55e85 years of age) were treated with
bazedoxifene 20 or 40 mg/day, raloxifene 60 mg/day, or pla-
cebo [14]. Among subjects with prevalent fracture, bazedox-
ifene 20 and 40 mg and raloxifene 60 mg significantly reduced
the risk of new vertebral fractures relative to placebo by 45%
(HR 0.55, 95% CI 0.32e0.94), 38% (HR 0.62, 95% CI
0.37e1.05), and 43% (HR 0.57, 95% CI 0.34e0.97), respec-
tively. In a post hoc analysis of a subgroup of women at higher
fracture risk (femoral neck T-score  3.0 and/or 1 mod-
erate or severe vertebral fracture or multiple mild vertebral
fractures; n ¼ 1772), bazedoxifene 20 mg produced a 50% and
44% reduction in nonvertebral fracture risk relative to placebo
(P ¼ 0.02) and raloxifene 60 mg (P ¼ 0.05), respectively.
Bazedoxifene treatment of postmenopausal women with
osteoporosis significantly reduced the risk of vertebral fracture
in the total subjects as well as subjects with pre-existing
Table 1
Risk reduction of vertebral or nonvertebral fractures among patients with prevalent fractures
Pharmacologic agent Study Patients with prevalent fractures (overall population or subgroup) Fracture risk Reference
Vertebral Nonvertebral
SERM
Raloxifene MORE Severe vertebral fracturesa (subgroup) RR 0.74 RH 0.53 11
Prevalent vertebral fractures (subgroup) RR 0.66/RR 0.54b 12
CORE Prevalent vertebral fractures (subgroup) HR 0.78 13
Bazedoxifene Phase 3 trial Prevalent vertebral fractures (subgroup) HR 0.55/HR 0.62c 14
1 moderate or severe vertebral fracture or multiple mild vertebral
fractures and/or FN T-score  3.0 (subgroup)
HR 0.5 14
Bisphosphonates
Alendronate FIT 1 vertebral fracture (overall population) RR 0.53/RH 0.45d RH 0.72/RH 0.49g 15
Risedronate VERT-NA 1 vertebral fracture (overall population) RR 0.59 RR 0.6 16
VERT-MN 2 vertebral fractures (overall population) RR 0.51 RR 0.67 17
Ibandronate BONE 1e4 prevalent vertebral fractures (overall population) RR 0.38 RR 0.31 18
1e4 prevalent vertebral fractures and FN T-score < 3.0 (subgroup) 18
Zoledronate HORIZON-PFT Prevalent vertebral fractures (63% of overall population) RR 0.30 HR 0.75/HR 0.59h 20
HORIZON-RFT Hip fracture (overall population) HR 0.54e HR 0.73/HR 0.70i 22
RANKL monoclonal antibody
Denosumab FREEDOM 2 vertebral fractures of any degree of deformity or 1 vertebral
fracture of moderate or severe deformity (subgroup)
RR 0.45 24
Parathyroid hormone
Teriparatide FPT 1 moderate vertebral fracture or 2 mild atraumatic vertebral
fractures (overall population)
RR 0.35/RR 0.31f RR 0.47/RR 0.46j 26
BONE: the oral ibandronate osteoporosis vertebral fracture trial in North America and Europe, CORE: the continuing outcomes relevant to Evista, FIT: the fracture intervention trial, FN: femur neck, FREEDOM:
the fracture reduction evaluation of denosumab in osteoporosis every 6 months, FPT: the fracture prevention trial, HORIZON-PFT: the health outcomes and reduced incidence with zoledronic acid once yearly-
pivotal fracture trial, HORIZON-RFT: the health outcomes and reduced incidence with zoledronic acid once yearly-recurrent fracture trial, HR: hazard ratio, MORE: the multiple outcomes of raloxifene
evaluation, RANKL: receptor activator of nuclear factor kappa-B ligand, RH: relative hazard, RR: relative risk, SERM: selective estrogen receptor modulator, VERT-NA: the vertebral efficacy with risedronate
therapy-North America, VERT-MN: the vertebral efficacy with risedronate therapy-multinational.
a Vertebral fracture severity assessed by the visual semiquantitative method.
b RR 0.66 for raloxifene 60 mg and RR 0.54 for raloxifene 120 mg.
c HR 0.55 for bazedoxifene 20 mg and HR 0.62 for bazedoxifene 40 mg.
d RR 0.53 for morphometric vertebral fracture and RH 0.45 for clinical vertebral fracture.
e HR 0.54 for clinical vertebral fracture.
f RR 0.35 for teriparatide 20 mg and RR 0.31 for teriparatide 40 mg.
g RH 0.72 for any clinical fracture including clinical vertebral fracture and RH 0.49 for hip fracture.
h HR 0.75 for nonvertebral fracture and HR 0.59 for hip fracture.
i HR 0.73 for nonvertebral fracture and HR 0.70 for hip fracture.
j RR 0.47 for teriparatide 20 mg and RR 0.46 for teriparatide 40 mg.
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reduction in the incidence of nonvertebral fractures in subjects
at higher risk for fracture.
3. Bisphosphonates3.1. AlendronateIn the randomized Fracture Intervention Trial (FIT) of ef-
fect of alendronate on risk of fracture in women with existing
vertebral fracture [15], 2027 women aged 55e81 years with
low femoral neck BMD and existing vertebral fracture were
randomly assigned placebo or alendronate and followed up for
3 years. Mean age was 71 years. New vertebral fractures
(morphometric and clinical), the primary endpoint, were
assessed. Eight percent of women in the alendronate group had
one or more new morphometric vertebral fractures compared
with 15% in placebo group (RR 0.53, 95% CI 0.41e0.61).
Also, alendronate significantly reduced clinical vertebral
fracture risk compared with in the placebo group after 3-year
follow up period (RH 0.45, 95% CI 0.27e0.72). The risk of
any clinical fracture was lower in the alendronate than in the
placebo group (RH 0.72, 95% CI 0.58e0.90). The risk of hip
fracture and wrist fracture for alendronate vs. placebo was
0.49 (95% CI 0.23e0.99) and 0.52 (95% CI 0.31e0.87),
respectively. Therefore, alendronate substantially reduces the
risk of vertebral fractures, as well as hip fractures in post-
menopausal women with prevalent vertebral fractures.3.2. RisedronateA representative randomized clinical trial of risedronate in
postmenopausal women with vertebral fracture (VERT-NA)
was reported in 1999 [16]. This clinical trial included 2,458
postmenopausal women younger than 85 years with at least 1
vertebral fracture. Subjects were randomly assigned to receive
risedronate or placebo for 3 years and the mean age of the
subjects was 69 years. Risedronate significantly decreased the
risk of new vertebral fracture compared with placebo over 3
years (RR 0.59, 95% CI 0.43e0.82). A significant reduction of
65% in vertebral fracture risk was seen in the first year of
treatment (95% CI 0.38e0.81). Also, risedronate reduced the
cumulative incidence of non-vertebral fractures by 39% over 3
years (95% CI 0.06e0.61). Reginster et al. [17] reported the
effects of risedronate on vertebral fracture in 1,226 post-
menopausal women with two or more prevalent vertebral
fracture in Europe and Australia (VERT-MN) for 3 years.
Risedronate reduced the risk of new vertebral fractures by
61% within the first year and 49% over 3 years compared with
control. However, non-vertebral fracture risk reduction was
33% compared with control over 3 years (P ¼ 0.06).3.3. IbandronateIn terms of ibandronate effects on severe osteoporosis, the
oral ibandronate Osteoporosis vertebral fracture trial in NorthAmerica and Europe (BONE) study has been the representa-
tive multicenter trial for oral ibandronate, which included
2946 postmenopausal women for 3 years [18]. The mean age
of the subjects was 69 years, and 93e94% had at least one
prevalent fracture and 42e44% were with at least two preva-
lent fractures. The protective effect on new vertebral fracture
was remarked from year 2 and 62% significant risk reduction
at year 3. However, nonvertebral fracture risk reduction was
69% only in the high risk group whose femoral neck BMD T-
score was lower than 3.0. The Dosing IntraVenous Admin-
istration (DIVA) study compared intravenous (IV) ibandronate
vs. oral regimen for one year in the United States and Europe
[19]. The mean age of the 1395 postmenopausal women was
65.5 years and 41.8e43.7% had a prevalent fracture. IV
ibandronate increased BMD of all sites compared with oral
ibandronate, but no difference of clinical vertebral fracture
risk was found in one year. Thus, oral and IV ibandronate
reduce vertebral fracture risk in severe osteoporosis with
prevalent fracture, but the risk reduction of nonvertebral
fracture has been reported only in high risk group with femoral
neck BMD T-score less than 3.0. Some caution is needed
when applying ibandronate for severe osteoporosis, since the
drug is indicated only for postmenopausal women and the risk
reduction of nonvertebral or wrist fracture has limited
outcome.3.4. ZoledronateAmong various bisphosphonates, zoledronic acid has long
been used and shown to be effective for hypercalcemia from
cancers or bone metastasis. For osteoporosis and fracture
prevention, the Health Outcomes and Reduced Incidence with
Zoledronic acid Once Yearly-Pivotal Fracture Trial (HORI-
ZON-PFT) is the representative trial with yearly injection of
zoledronic acid in 3,889 postmenopausal women for 3 years
held in the USA, Europe, and Asia [20]. The mean age of the
subjects was 73 years and 63e79% had prevalent vertebral
fracture. The morphometric vertebral fracture risk was
reduced by 70%, nonvertebral fracture risk by 25%, and hip
fracture risk by 41%. The prolonged effect of zoledronic acid
was compared in the HORIZON-PFT extension study, which
compared a 3-year extension of zoledronic acid or change to
placebo after conventional therapy [21]. The subjects over
50% had a femoral BMD T-score less than 2.5 and 60% of
subjects had at least one prevalent vertebral fracture. The
morphometric vertebral fracture risk was reduced by 49% in
the 6-year extension group but no difference was evident in the
risk of nonvertebral or hip fracture. No significant differences
in long-term side effects were reported. The HORIZON
Recurrent Fracture Trial reported a 35% reduction of recurrent
fracture, 46% of clinical vertebral fracture, and 27% of non-
vertebral fracture in 2,127 men and women with recent repair
for low-trauma hip fracture [22]. Moreover, mortality was
significantly reduced by 28% in the 3-year trial. Thus, yearly
injection of 5 mg zoledronic acid is effective in reducing
clinical and morphometric vertebral, nonvertebral, and hip
17H.S. Choi et al. / Osteoporosis and Sarcopenia 2 (2016) 13e19fracture risk, and also reduces recurrent fractures and mortality
in high risk groups of both men and postmenopausal women
with severe osteoporosis.
4. RANKL monoclonal antibody4.1. DenosumabFracture prevention with denosumab in postmenopausal
women with osteoporosis was demonstrated in the Fracture
Reduction Evaluation of Denosumab in Osteoporosis Every 6
Months (FREEDOM) Trial [23]. FREEDOM was a 3-year,
randomized, double-blind, placebo-controlled, phase 3 trial
that enrolled 7868 postmenopausal women with osteoporosis.
The subcutaneous administration of 60 mg of denosumab
every 6 months for 36 months significantly reduced the risk of
new radiographic vertebral fracture by 68% (RR 0.32, 95% CI
0.26e0.41; P < 0.001). Denosumab reduced the risk of hip
fracture by 40% (HR 0.60, 95% CI 0.37e0.97; P ¼ 0.04) and
also reduced the risk of nonvertebral fracture by 20% (HR
0.80, 95% CI 0.67e0.95; P ¼ 0.01). A post hoc analysis of
FREEDOM trial evaluated fracture incidence in women with
higher-risk for vertebral or hip fractures [24]. As compared
with placebo, treatment with denosumab reduced the inci-
dence of new vertebral fractures by 55% among women with
multiple prevalent vertebral fractures and/or moderate or se-
vere vertebral deformity (16.6% placebo vs. 7.5% denosumab;
P < 0.001). Denosumab also reduced the risk of new vertebral
fractures by 60% in those with multiple and/or moderate or
severe vertebral deformities in addition to a femoral neck
BMD T-score of 2.5 or less (20.1% placebo vs. 8.1%
denosumab; P ¼ 0.001). Denosumab treatment also signifi-
cantly reduced the risk of hip fractures in subjects aged 75
years or older by 62% (2.3% placebo vs. 0.9% denosumab;
P < 0.01) or with a baseline femoral neck BMD T-score of
2.5 or less by 47% (2.8% placebo vs. 1.4% denosumab;
P ¼ 0.02). The anti-fracture efficacies in higher-risk subgroup
over 3 years were consistent with those reported for the overall
FREEDOM population. These analyses demonstrated that
denosumab reduces the risk of both new vertebral and hip
fractures, regardless of the underlying risk and that the higher
absolute fracture risk observed in the higher-risk subgroups is
associated with greater absolute risk reduction with denosu-
mab treatment.
5. Parathyroid hormone5.1. TeriparatideTeriparatide is an anabolic agent composed of the first 34
amino acids of recombinant human parathyroid hormone.
Teriparatide stimulates bone formation by osteoblasts and
subsequently bone resorption by osteoclasts, and has anabolic
effects on bone with an anabolic window [25]. Because of this
unique anabolic action, teriparatide showed superior efficacy
in treating osteoporosis and preventing fractures. In the
Fracture Prevention Trial, daily subcutaneous injection ofteriparatide for 18 months in postmenopausal women with
prior vertebral fractures increased BMDs by 9.7% and 2.8% at
the lumbar spine and femur neck, respectively [26]. Moreover,
teriparatide treatment reduced the risks of vertebral and non-
vertebral fracture by 65% and 53%, respectively, in the post-
menopausal women [26]. Teriparatide showed superior
efficacy on increasing BMD at lumbar spine compared to
alendronate (10.3% vs. 5.5% in areal BMD and 19.0% vs.
3.8% in volumetric BMD, P < 0.05 respectively) [25].
Although prior treatment with anti-resorptive agents modestly
blunted the anabolic efficacy of teriparatide, teriparatide
administration was effective in increasing BMD in post-
menopausal women with previous anti-resorptive agents use
[27,28]. Teriparatide has also been effective in male osteo-
porosis. Daily 20 mg subcutaneous injection of teriparatide
significantly increased BMDs by 13.5% at lumbar spine and
by 2.9% at femur neck in one study [29]. Teriparatide treat-
ment provided efficacy in increasing BMD and reducing
fractures in glucocorticoid induced osteoporosis with better
outcomes in decreasing vertebral fractures and no differences
in non-vertebral fractures compared to the alendronate group
[30]. However, the combination therapy of teriparatide with
anti-resorptive agents is not recommended because there has
been no evidence of synergistic effects between those two
drugs [31,32]. The common side effects in using teriparatide
are mild gastrointestinal symptoms, especially nausea, and
headache. The total exposure period is limited to 24 months,
and switch to anti-resorptive agents is recommended to extend
the anabolic effects of prior teriparatide [33].
6. Discussion
The clinical significance associated with osteoporosis is the
occurrence of fragility fractures at various sites and the goal of
osteoporosis management is prevention of fractures and ulti-
mately reduction in morbidity and mortality. Therefore, it is
clinically important to identify those who are at higher risk of
fractures and more likely to benefit from osteoporosis man-
agement. In 1994, the WHO published the current definition of
osteopenia and osteoporosis based on the BMD T-score [7].
The criteria were developed based on the evidence indicating
that BMD can predict fracture risk [34e36], although it is now
generally accepted that fracture risk is determined not only by
BMD but also by other structural and functional factors
associated with bone quality. The WHO also defined severe
osteoporosis as the presence of fragility fracture in addition to
BMD T-score of 2.5 or less. This concept of severe osteo-
porosis is also supported by the fact that previous osteoporotic
fractures increase the risk of subsequent fractures [8,9].
However, the WHO definition of severe osteoporosis does not
take into account the number and severity of prevalent verte-
bral fractures, which have been independently associated with
subsequent vertebral or nonvertebral fractures [11,37]. A
previous study by Lindsay et al. showed that the presence of
one vertebral fracture increased the risk of new vertebral
fracture by 2.6-fold during the initial year of the study
compared with the incidence in subjects without vertebral
18 H.S. Choi et al. / Osteoporosis and Sarcopenia 2 (2016) 13e19fracture at baseline, while the presence of two or more
vertebral fracture was associated with increased risk of new
vertebral fracture by as much as 7.3-fold [8]. Furthermore,
excess mortality rates following fractures of the vertebrae
[38e40] and particularly of the hip [2,3,40,41] were also
demonstrated in many studies. Mortality rates following hip
fracture were reported to range from 10% to 45% in the first
year [41]. The number of prevalent vertebral fractures is also
associated with increased mortality. A prospective USA cohort
study with a mean follow-up of 8.3 years showed that mor-
tality rose with greater numbers of vertebral fractures, from 19
per 1000 woman-years in women with no fractures to 44 per
1,000 woman-years in those with 5 or more fractures [38]. In
contrast, no excess mortality was reported among patients who
sustain a distal forearm, foot, or ankle fractures [39e41].
Given these various relationships between fractures and their
consequences, many clinicians and researchers believe that the
current WHO definition is not sufficient to reflect the diverse
spectrum of osteoporosis or severe osteoporosis, which can
encompass various number and severity of prevalent fractures.
To overcome these shortcomings, we need new criteria that
stratify the disease severity in detail to assess the fracture risk
more precisely and provide a basis for more aggressive
treatment options.
In this regard, we propose a concept of ‘advanced severe
osteoporosis’ to provide more accurate assessment of the
disease and allow more aggressive managements. We think
that number and location of prevalent fractures should be
taken into account to further stratify the concept of severe
osteoporosis. Therefore, we defined the advanced severe
osteoporosis by the presence of proximal femur fragility
fracture or two or more fragility fractures in addition to BMD
T-score of 2.5 or less. We expect this new concept of
advanced severe osteoporosis will provide a basis for more
aggressive managements for osteoporotic patients with mul-
tiple fractures [42].
In this topic review of severe osteoporosis, we reviewed the
anti-osteoporotic agents and found that four classes of estab-
lished medications have strong evidence enough to be used in
severe osteoporosis or osteoporosis with prevalent fractures.
Therefore, we recommend SERMs, bisphosphonates, RANKL
monoclonal antibody, and parathyroid hormone for the medi-
cal treatment of severe osteoporosis, based on the clinical
trials and post-hoc analyses. In cases of advanced severe
osteoporosis or osteoporosis that does not respond to previous
anti-osteoporotic treatments, we also recommend parathyroid
hormone as an anabolic agent, and bisphosphonates and
RANKL monoclonal antibody as more effective antiresorptive
agents, which showed definite anti-fracture efficacy not only
for vertebral fracture but also for non-vertebral or hip fracture
based on the results of pivotal clinical trials.
In conclusion, we need more precise assessment of osteo-
porosis and further stratification of the disease by number and
location of prevalent fractures in addition to BMD. For those
with severe osteoporosis or advanced severe osteoporosis,
more effective managements should be warranted to decrease
the morbidity and mortality associated with osteoporosis.Considering the detrimental effects of osteoporosis-related
fragility fractures on future public health in these aging soci-
eties, we desperately need a national policy allowing more
aggressive treatment options for this disease.
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